To assess the therapeutic efficacy of the TLR9 agonist SD101 in an immunocompetent osteosarcoma mouse model (mOS69), tumor cells were injected subcutaneously into both flanks and only one lesion was treated. This evidence concerns the gene TLR9 and neoplasm.